Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy

Božović, Ivo; Perić, Marina; Azanjac, Ana Arsic; Palibrk, Aleksa; Bulatović, Ivana; Aleksić, D; Perić, Stojan; Basta, Ivana

doi:10.1007/s11136-021-02838-w

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strengths of this study on real-world data are the focus on treatment-naïve patients, the prospective multicenter design, and the relatively long follow-up. Prospective data were not limited to accepted clinical disability and impairment outcomes, but also included important outcome measures such as pain, fatigue, additional support and quality of life assessments that are infrequently described in a prospective nature in the literature [ 47 , 48 ]. The sample size was too small to allow comparison between treatment groups.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study

et al. 2021

View full text Add to dashboard Cite

Objective To assess clinical outcome in treatment-naive patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods We included adult treatment-naive patients participating in the prospective International CIDP Outcome Study (ICOS) that fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIDP. Patients were grouped based on initial treatment with (1) intravenous immunoglobulin (IVIg), (2) corticosteroid monotherapy or (3) IVIg and corticosteroids (combination treatment). Outcome measures included the inflammatory Rasch-built overall disability scale (I-RODS), grip strength, and Medical Research Council (MRC) sum score. Treatment response, treatment status, remissions (improved and untreated), treatment changes, and residual symptoms or deficits were assessed at 1 year. Results Forty patients were included of whom 18 (45%) initially received IVIg, 6 (15%) corticosteroids, and 16 (40%) combination treatment. Improvement on ≥ 1 of the outcome measures was seen in 31 (78%) patients. At 1 year, 19 (48%) patients were still treated and fourteen (36%) patients were in remission. Improvement was seen most frequently in patients started on IVIg (94%) and remission in those started on combination treatment (44%). Differences between groups did not reach statistical significance. Residual symptoms or deficits ranged from 25% for neuropathic pain to 96% for any sensory deficit. Conclusions Improvement was seen in most patients. One year after the start of treatment, more than half of the patients were untreated and around one-third in remission. Residual symptoms and deficits were common regardless of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CIDP, being a chronic disease, can lead to different functional complications of unpredictable duration and sequelae. In addition to physical disability, factors like pain, fatigue, anxiety, and depression may significantly affect the patient's quality of life and also the course and outcome of the disease [57,58]. It is well known that neuropathic pain severity can impact patients' quality of life more than functional disability, suggesting that its symptomatic management might be one of the most relevant targets in the treatment of peripheral neuropathies [59,60].…”

Section: Discussionmentioning

confidence: 99%

Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study

Cocito,

Peci,

Torrieri

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease. Neuropathic pain (NP), related to peripheral inflammation, is among its earliest manifestations. This preliminary open-label investigation aimed to evaluate the efficacy of ultramicronized Palmitoylethanolamide (umPEA) in the management of NP. Methods: A total of 14 patients with CIDP, already undergoing immunoglobulin (Ig) therapy, were divided into two groups: Group A received umPEA 600 mg twice daily in addition to Ig for 60 days, followed by Ig alone until the end of the observation (180 days); Group B received Ig alone for 120 days and subsequently umPEA + Ig in the last 60 days of the study. Painful symptom intensity and quality of life were assessed by the Numeric Rating Scale, Neuropathic Pain Symptoms Inventory, and Five Dimensions Health Questionnaire. The safety umPEA profile was evaluated. Results: UmPEA in addition to immunoglobulins allowed for a significant improvement over time in all NP symptoms intensity (p = 0.0007) and in patients’ quality of life (p = 0.0036). Conclusions: This study suggests umPEA as a safe and effective treatment in addition to immunoglobulins to improve NP, ameliorating the patient’s health status. These results highlight the importance of neuroinflammation modulation in the management of CIDP’s painful symptoms, drawing attention to umPEA’s potential use also in neuropathies of different etiologies.

show abstract

Gait analysis of a patient with severe motor impairment post- intensive care due to COVID-19: 1 year follow up and physical therapy

Ferreira,

Aquino,

Silva Filho

et al. 2023

Fisioter. mov.

View full text Add to dashboard Cite

Introduction Viral infections, such as infection by SARS-CoV-2, can affect gait biomechanics, but this effect can be overlapped by consequences of critical illness and time in intensive care unit. Objective To report biomechanical alterations during the clinical evolution of a post-COVID-19 patient who presented severe motor impairment after intensive care. Methods Data was collected from the patient’s chart at José Silveira Foundation and previous medical reports from the hospitalization period. The patient was wheelchair bound, with physiotherapy twice a week, and by the end of 1-year follow-up was able to walk independently. Three-dimensional gait analysis with kinetics and electromyography were conducted at three time points. Results All spatiotemporal gait parameters, kinematic, kinetic and electromyographic data was importantly altered when compared to the normal range of values. With physiotherapy, gait quality indicators showed important improvements and all muscles presented a significant increase in the magnitude of the electromyographic signal (at least a two-fold increase). Trunk kinematic alterations decreased significantly during this period. Kinetic and kinematic changes perceived in the hips, knees and ankles showed approximation to the expected pattern, however still without normalizing, and patient's muscle coordination improved over time. Conclusion This report has great clinical importance, as it describes, using an instrumented gait laboratory, the evolution of a patient with severe motor impairment post intensive care due to COVID-19, a condition in lack of description in the literature, which will help health professionals in the planning of rehabilitation strategies.

show abstract

Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy

Cited by 3 publications

References 19 publications

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study

Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study

Gait analysis of a patient with severe motor impairment post- intensive care due to COVID-19: 1 year follow up and physical therapy

Contact Info

Product

Resources

About